Stryker Q3 2025 Operating Results and Outlook

The provided sources are a transcript of the third quarter 2025 earnings call for Stryker and the corresponding press release detailing the operating results. The documents center on Stryker's strong financial performance, reporting $6.1 billion in net sales and 9.5% organic sales growth for Q3 2025. Key highlights include double-digit adjusted EPS growth of 11.1%, successful integration and performance of the recently acquired Inari business, and strong growth in the Orthopaedics segment (11.4% organic sales growth) driven by Mako installations. Management is raising the full-year 2025 outlook based on continued high demand, while acknowledging ongoing challenges like supply chain disruptions in the Medical business and increasing tariff headwinds expected to total around $200 million for the year. The sources also mention the strategic focus on margin expansion and remaining active in tuck-in mergers and acquisitions (M&A).